US00791X1000 - Common Stock
AEON BIOPHARMA INC
NYSEARCA:AEON (10/14/2024, 8:12:03 PM)
1.04
+0.04 (+4.42%)
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.
AEON BIOPHARMA INC
4040 Macarthur Boulevard, Suite 310
Newport Beach CALIFORNIA
P: 19492844555.0
Employees: 5
Website: https://www.aeonbiopharma.com/
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company...
AEON stock results show that AEON Biopharma beat analyst estimates for earnings per share the second quarter of 2024.
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – –...
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!
Here you can normally see the latest stock twits on AEON, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: